Mental health · Atlanta area, GA
Mental health studies in Atlanta area, GA
81 recruiting studies have a site in the Atlanta area. This page includes nearby cities such as Decatur, Marietta, Sandy Springs, Alpharetta.
81 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
Reunion Neuroscience Inc
- Location
- Atlanta, GA + 26 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Atlanta, GA + 43 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)
Transcend Therapeutics
- Location
- Atlanta, GA + 36 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Brexanolone Lifting Outcomes Of Moms
Lipocine Inc.
- Location
- Decatur, GA + 15 other US sites
- Eligibility basics
- Ages 15–45 · Women only
- RecruitingPhase 3
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
Bristol-Myers Squibb
- Location
- Atlanta, GA + 39 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
52-week Open Label Safety-Tolerability Study
LB Pharmaceuticals Inc.
- Location
- Atlanta, GA + 22 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
Bristol-Myers Squibb
- Location
- Atlanta, GA + 7 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Alkermes, Inc.
- Location
- Decatur, GA + 14 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 2
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
AbbVie
- Location
- Atlanta, GA + 32 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Atlanta, GA + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
Novartis Pharmaceuticals
- Location
- Decatur, GA + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Minerva Neurosciences
- Location
- Atlanta, GA + 12 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
AbbVie
- Location
- Decatur, GA + 30 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
LB Pharmaceuticals Inc.
- Location
- Snellville, GA + 12 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
LB Pharmaceuticals Inc.
- Location
- Atlanta, GA + 25 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Atlanta, GA + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
AbbVie
- Location
- Marietta, GA + 46 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
AbbVie
- Location
- Atlanta, GA + 32 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
atai Therapeutics, Inc.
- Location
- Decatur, GA + 33 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Atlanta, GA + 20 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Autobahn Therapeutics, Inc.
- Location
- Decatur, GA + 31 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Randomized Withdrawal Study in Patients With Schizophrenia
Vanda Pharmaceuticals
- Location
- Atlanta, GA + 21 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study of ALTO-101 in Patients With Schizophrenia
Alto Neuroscience
- Location
- Snellville, GA + 12 other US sites
- Eligibility basics
- Ages 21–55
- RecruitingPhase 2
Study of ALTO-300 in MDD
Alto Neuroscience
- Location
- Savannah, GA + 36 other US sites
- Eligibility basics
- Ages 18–70
Who these studies look for
Studies usually require a confirmed diagnosis and stable circumstances, and they monitor safety closely. If you are in crisis, contact a crisis line or emergency services rather than a study.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.